MARKET

KNSA

KNSA

Kiniksa Pharmaceuticals, Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

23.73
-1.80
-7.05%
After Hours: 23.05 -0.68 -2.87% 17:33 07/02 EDT
OPEN
24.99
PREV CLOSE
25.53
HIGH
25.24
LOW
23.25
VOLUME
397.12K
TURNOVER
--
52 WEEK HIGH
28.67
52 WEEK LOW
5.01
MARKET CAP
1.42B
P/E (TTM)
-10.6274
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KNSA stock price target is 37.75 with a high estimate of 40.00 and a low estimate of 33.00.

EPS

KNSA News

More
Kiniksa's Heart Drug, And Other News: The Good, Bad, And Ugly Of Biopharma
Seeking Alpha - Article · 3d ago
Company News for Jun 30, 2020
Zacks · 3d ago
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 3d ago
3 Strong Buy Coronavirus Stocks With Massive Upside Potential
TipRanks · 4d ago
Kiniksa Reports Positive Results of Pericarditis-Drug Trial
TheStreet.com · 4d ago
Why Kiniksa's Stock Is Trading Higher Today
Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) shares were trading higher Monday after the company's Phase 3 trial of Rilonacept showed statistically significant results.
Benzinga · 4d ago
5 Stocks With Recent Price Strength Amid Spike in Coronavirus
Zacks · 4d ago
NKLA, COTY among premarket gainers
Seeking Alpha - Article · 4d ago

Industry

Biotechnology & Medical Research
+0.68%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About KNSA

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases. The Company’s programs include Rilonacept, which is a protein for inhibiting interleukin-1 alpha and interleukin-1beta; Mavrilimumab, is a monoclonal antibody that antagonizes the signaling of granulocyte macrophage colony stimulating factor, or GM-CSF; KPL-716, is a monoclonal antibody that simultaneously inhibits the signaling of the cytokines interleukin-31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor beta, or OSMR beta; KPL-045 is a monoclonal antibody inhibitor of the CD30/CD30L interaction, a T-cell co-stimulatory receptor involved in activated T-memory cell function, and KPL-404, is a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity.
More

Webull offers kinds of Kiniksa Pharmaceuticals Ltd stock information, including NASDAQ:KNSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KNSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KNSA stock methods without spending real money on the virtual paper trading platform.